PhoenixBio Co.,Ltd. Logo

PhoenixBio Co.,Ltd.

A CRO providing humanized liver mouse models for preclinical drug studies.

6190 | T

Overview

Corporate Details

ISIN(s):
JP3803010002
LEI:
Country:
Japan
Address:
東広島市鏡山三丁目4番1号

Description

PhoenixBio is a contract research organization (CRO) specializing in translational animal models for the pharmaceutical industry. The company's core product is the PXB-mouse®, a proprietary chimeric mouse model featuring a liver that is highly repopulated (over 70%) with functional human hepatocytes. This humanized liver model is utilized globally in preclinical studies to evaluate drug metabolism, pharmacokinetics, and toxicity. In addition to supplying the PXB-mouse® and primary human hepatocytes (PXB-cells®), PhoenixBio provides comprehensive, quality-controlled contract study services to support drug discovery and early development projects.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-08-12 08:48
確認書
Japanese 8.0 KB
2022-08-12 08:47
四半期報告書-第22期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 137.5 KB
2022-06-29 04:50
内部統制報告書-第21期(令和3年4月1日-令和4年3月31日)
Japanese 22.1 KB
2022-06-29 04:47
確認書
Japanese 8.1 KB
2022-06-29 04:46
有価証券報告書-第21期(令和3年4月1日-令和4年3月31日)
Japanese 919.9 KB
2022-02-14 07:50
四半期報告書-第21期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 149.3 KB
2021-11-12 07:48
四半期報告書-第21期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 173.1 KB
2021-08-13 08:47
四半期報告書-第21期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 142.6 KB
2021-06-25 03:49
内部統制報告書-第20期(令和2年4月1日-令和3年3月31日)
Japanese 22.2 KB
2021-06-25 03:47
確認書
Japanese 8.0 KB
2021-06-25 03:45
有価証券報告書-第20期(令和2年4月1日-令和3年3月31日)
Japanese 977.0 KB
2021-02-12 08:14
四半期報告書-第20期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese 135.2 KB
2020-11-13 07:49
四半期報告書-第20期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 164.2 KB
2020-08-12 08:49
四半期報告書-第20期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese 133.9 KB
2020-06-26 03:17
有価証券報告書-第19期(平成31年4月1日-令和2年3月31日)
Japanese 973.9 KB

Automate Your Workflow. Get a real-time feed of all PhoenixBio Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PhoenixBio Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PhoenixBio Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.